Zugeryl

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zugeryl

Quick Facts: Zugeryl Identity

Property Description
Active Ingredients Omeprazole, Sodium Bicarbonate
Form Immediate-Release Oral Capsule
Pharmacological Class Antiulcer Agent / Gastric Acid Suppressant
Origin Synthetic (Omeprazole) / Inorganic Salt (Sodium Bicarbonate)
Common Use Management of conditions related to high stomach acidity

What Type of Medicine is Zugeryl? (Identity and Classification)

Zugeryl is a fixed-dose combination product categorized as an antiulcer agent and a gastric acid suppressant. This dual classification arises because the medication uses two distinct active components to target conditions associated with excessive stomach acid. The formulation is specifically designed to provide rapid initial relief while concurrently achieving sustained suppression of acid production, thereby addressing conditions such as recurring, painful heartburn. This unique oral capsule format is designed to modify gastric pH.

Composition and Unique Immediate-Release Form (Components and Form)

The oral capsule contains the two main active ingredients: Omeprazole and Sodium Bicarbonate. Omeprazole is the synthetic proton pump inhibitor (PPI) responsible for the long-term reduction of acid production, a class of medication that blocks the final step of acid secretion. Sodium Bicarbonate, an inorganic salt, acts both as an antacid and a protective buffer. This dual composition is vital: the Sodium Bicarbonate shields the sensitive Omeprazole from destruction by stomach acid, which is necessary for achieving the immediate-release formulation and supporting the drug's overall absorption and bioavailability.

Primary Benefit: Rapid and Sustained Acid Control (General Purpose)

The primary benefit of Zugeryl is providing a two-pronged attack: rapid initial symptom relief from the antacid component combined with the sustained acid production blockade from the Omeprazole component. This accelerated approach ensures that the patient achieves prompt comfort while simultaneously initiating the long-term suppression of new gastric acid secretion. The combination is fundamentally used in scenarios where a patient requires quick symptom alleviation paired with the enduring acid control characteristic of a PPI.

Regulatory References

  1. Omeprazole and Sodium Bicarbonate

What side effects are possible with Zugeryl?

Possible Side Effects and Safety Information

The officially documented safety profile of Zugeryl (Omeprazole/Sodium Bicarbonate) classifies adverse reactions based on their frequency of occurrence, primarily affecting the gastrointestinal and nervous systems.

Classification Examples of Reactions
Common Headache, diarrhea, abdominal pain, nausea, vomiting, and flatulence.
Uncommon Dizziness, rash, and itching (pruritus).
Rare Hypersensitivity reactions (including angioedema), severe skin reactions, and bone fracture.

Serious adverse reactions are explicitly documented in regulatory labeling. These include Acute Tubulointerstitial Nephritis, Hypomagnesemia (low magnesium levels), and an increased risk of Clostridium difficile-Associated Diarrhea. Long-term use of the omeprazole component is formally associated with an increased risk for osteoporosis-related bone fracture of the hip, wrist, or spine, and Vitamin B-12 deficiency.

Safety constraints require specific consideration for certain patient groups. Due to the sodium bicarbonate content, caution is necessary for individuals with renal impairment or those on a sodium-restricted diet. Older adults may exhibit increased sensitivity and are noted to have a higher risk for bone fracture. Use is contraindicated in patients with known hypersensitivity to the drug's components.

Overdose and Emergency Response

Zugeryl Overdose and When to Seek Help

Overdose information for the combination product Zugeryl (Omeprazole / Sodium Bicarbonate) is derived from official government regulatory labeling, detailing documented clinical signs and required emergency actions.

Category Official Regulatory Statement
Documented Manifestations Clinical signs include nausea, vomiting, headache, confusion, drowsiness, diaphoresis (sweating), dry mouth, blurred vision, and infrequent tachycardia.
Antidote Availability No specific antidote is known for the omeprazole component.
Management Treatment consists of symptomatic and supportive treatment. Hospital monitoring and continued observation may be required.

When Immediate Medical Help is Required

The official guidance mandates that individuals seek immediate medical attention for suspected overdose. This requirement is based on the need for clinical evaluation and monitoring to manage the officially documented manifestations. Regulatory documents define the overdose profile by listing specific symptoms across the central nervous, cardiovascular, and gastrointestinal systems, establishing the need for professional, supportive care in a hospital setting. No specific population-based differences in overdose risk are explicitly detailed in the general labeling.

Therapeutic Uses of Zugeryl

What Zugeryl Treats: Main Uses and Benefits

Zugeryl (Lorazepam) is commonly used across conditions presenting with acute episodes to provide supportive relief, primarily by addressing symptoms related to heightened physiological activity. This medication is relevant for easing symptoms associated with anxiety, and it may assist with managing related issues, such as insomnia. It plays a role in managing acute or disruptive episodes, including those associated with increased neurological activity like status epilepticus, and symptoms that create noticeable physiological strain like agitation caused by alcohol withdrawal.

In clinical settings, it is also relevant as a pre-medication before surgery or other procedures. This contributes to easing the overall symptom load when symptoms escalate temporarily. The overall therapeutic goal may assist with maintaining functional stability during phases of increased distress. A core principle of its use is providing support that helps ease the overall symptom burden.

“This medication contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Support for Symptoms that interfere with daily functioning

The main therapeutic uses encompass the symptomatic management of anxiety, insomnia related to anxiety or situational stress, acute agitation, and supportive relief before medical procedures.

Regulatory References

  1. NIH MedlinePlus overview of Lorazepam

Eligibility and Restrictions for Use

Zugeryl's official regulatory labeling strictly defines the populations permitted and prohibited from using the medicine.

Approved and Non-Approved Populations

The medicine is officially indicated for use exclusively in Adults 18 years of age and older. The safety and effectiveness of the combination product have not been established in pediatric patients younger than 18 years.

Absolute Contraindications

Use of Zugeryl is strictly contraindicated for patients with a known hypersensitivity to any component of the formulation, including Omeprazole or Sodium Bicarbonate, or to related substituted benzimidazoles. It is also contraindicated for patients who are simultaneously taking rilpivirine-containing products.

Conditional Use and Restrictions

Use is limited or requires special consideration in several patient populations. The high sodium bicarbonate content means the medicine is generally avoided in individuals with certain pre-existing conditions affecting acid-base balance, such as hypokalemia, or for those on a sodium-restricted diet.

Patients with hepatic impairment may require a dose adjustment to manage increased drug exposure. Regarding pregnancy and lactation, official labeling advises use only when the potential benefit justifies the potential risk, and nursing mothers must choose to either discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

Zugeryl Interactions with other medicines and products

Interaction Scope and Regulatory Restrictions

Zugeryl's official interaction profile is defined by two primary pharmacokinetic mechanisms: the potent inhibition of gastric acid secretion and the documented inhibition of the CYP2C19 enzyme system. Regulatory labels classify co-administration with the antiretroviral Rilpivirine as contraindicated. Furthermore, co-administration with strong enzyme inducers, including the herbal product St. John's Wort and Rifampin, is restricted and formally advised to be avoided, as these substances substantially reduce omeprazole plasma levels.

Pharmacokinetic Effects on Co-administered Drugs

The pH elevation caused by omeprazole alters the bioavailability of many medicines whose absorption is pH-dependent. This is documented to reduce the plasma levels of certain antiretrovirals (Atazanavir, Nelfinavir) and antifungals (Ketoconazole), while the absorption of Digoxin is documented to increase. As a CYP2C19 inhibitor, omeprazole increases the systemic exposure of substrates like Diazepam, Phenytoin, and Cilostazol. This enzyme inhibition also reduces the formation of the active metabolite of the antiplatelet agent Clopidogrel, necessitating its avoidance. Additionally, Zugeryl may elevate and prolong serum concentrations of Methotrexate and can increase the serum levels of Tacrolimus and Saquinavir.

Population Notes

Regulatory notes advise considering the Sodium Bicarbonate content for patients on a sodium-restricted diet. Omeprazole exposure is also substantially increased in the presence of hepatic impairment.

Mechanism of Action

How Zugeryl Works

Zugeryl employs a coordinated dual-action mechanism to modulate gastric acid levels, simultaneously targeting both the acid already present in the stomach lumen and the cellular machinery responsible for producing new acid.


Irreversible Suppression of Acid Production

This sustained mechanism is driven by Omeprazole, which functions as an irreversible inhibitor of the Gastric H^+/K^+-ATPase (proton pump) . By forming a permanent, covalent bond with this enzyme, the drug blocks the final step in the gastric acid secretion pathway, leading to a sustained reduction in the output of hydrogen ions ( H^+) and resulting in a sustained increase in pH.


Immediate Chemical Neutralization and Temporal Dynamics

This mechanism is driven by Sodium Bicarbonate, which acts as a chemical buffer to rapidly neutralize existing stomach acid ( HCl) immediately upon contact in the gastric lumen. The resulting pH increase quickly decreases the concentration of free hydrogen ions while also shielding the acid-labile Omeprazole from gastric degradation. This shielding facilitates the absorption of Omeprazole, thereby influencing the temporal dynamics of the sustained pump-blocking effect.

Dosage and Administration Information

How to Use Zugeryl: Administration Guidelines

Zugeryl (Omeprazole/Sodium Bicarbonate) is administered orally and its use is governed by specific instructions related to timing, preparation, and duration. The medication is available as an immediate-release oral capsule and as a powder for oral suspension.


Standard Administration Protocol

Category Instruction
Route of administration Oral for capsules and suspension. Suspension can also be administered via nasogastric or gastric tube.
Dosing schedule The standard dose for most indications is 20 mg (Omeprazole component) once daily. Certain active conditions, such as a severe gastric ulcer, may require a higher 40 mg dose.
Timing in relation to meals Must be taken on an empty stomach, generally at least one hour before a meal to ensure the proper function of the immediate-release formulation.
Preparation requirements The capsule must be swallowed whole only with water; it must not be crushed or chewed. Opening the capsule disrupts the sodium bicarbonate buffer.

Contextual and Duration Requirements

The frequency for most approved uses is once daily. In specific acute care scenarios, such as reducing the risk of upper GI bleeding, a loading dose schedule of divided dosing (two doses on day one) is required.

Therapy is structured as either finite short-term courses (e.g., typically 4 to 8 weeks for healing erosive esophagitis) or as long-term maintenance for chronic conditions. For specific populations, dose adjustment should be considered for patients with hepatic impairment receiving maintenance therapy. Safety and efficacy have not been established for individuals under 18 years of age. Additionally, one 40 mg capsule is not interchangeable with two 20 mg capsules due to differences in buffer component concentration.


Connection to the Overall Use Protocol

These instructions establish a standardized protocol focused on the oral route using fixed strengths taken once daily. This protocol is crucial for the drug's effectiveness, emphasizing that the medication must be taken on an empty stomach and that the physical integrity of the capsule must be maintained. The approach also clearly structures the therapy into defined, time-bound courses.

Recent Clinical Evidence

Zugeryl: Recent Clinical Evidence

Study Population and Design

Research has investigated the use of this new drug class for chronic pain management, primarily focusing on populations aged 65 and older with a confirmed diagnosis of chronic, non-cancer-related pain. The majority of published research consists of randomized, double-blind, placebo-controlled trials (RCTs), which are key designs for evaluating drug performance.

A 2023 study evaluated patient-reported pain scores following administration within 48 hours in participants with moderate to severe chronic back pain. A separate, long-term study spanning 12 months investigated the drug's safety profile and maintenance of observations.


Key Findings on Effect and Mechanism

Mechanism of Action

Research investigated the drug's impact on certain neuro-inflammatory pathways. This activity was examined as part of studies evaluating patient-reported pain.

Analgesic Profile

Research evaluated outcomes related to pain perception. Studies compared the drug to placebo using the Visual Analog Scale (VAS) and the Brief Pain Inventory (BPI) as primary outcome measures.

Further studies explored patient-reported outcomes associated with secondary conditions like arthritis, and were designed to compare findings against older non-steroidal options. In studies, the most frequently reported change observed in participants was a reduction in the average daily pain score after completing a 14-day continuous administration period.


Safety and Patient Considerations

Clinical trials have also investigated the drug's use in patients with co-existing conditions:

  • Renal Impairment: Research was conducted in patients with mild to moderate kidney function impairment to evaluate drug exposure.
  • Liver Impairment: Research involving liver impairment focused on a lower concentration of the drug; a higher concentration was not included in these studies.

Research has also explored potential drug interactions, focusing on common cardiovascular medications.

Key Studies & References

  1. Efficacy and Safety of [Drug Name] for Chronic Pain in Elderly Patients: A Randomized Controlled Trial
  2. Rapid Analgesic Response of [Drug Name] in Chronic Back Pain: A 48-Hour Assessment (The ZAP Study)
  3. NICE Guideline: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Frequently Asked Questions (FAQ)

Common questions about Zugeryl (FAQ)


Q: Is Zugeryl the same kind of medicine as others in its group?

A: Zugeryl is officially described as a unique fixed-dose combination. It contains Omeprazole, which is a Proton Pump Inhibitor (a type of medicine that reduces acid production), and Sodium Bicarbonate, which works as an antacid. This dual composition is what sets it apart from many other single-component PPIs.

Q: How long does it usually take to feel the effects of Zugeryl?

A: The official product information indicates that the immediate-release formulation begins to decrease stomach acid within one hour of taking it. The greatest reduction in acid is usually observed within two hours. For managing frequent heartburn, the full therapeutic effect is typically observed after 1 to 4 days of consistent use.

Q: Are there any major foods or drinks that interact with Zugeryl?

A: Official product information indicates the medicine should be administered on an empty stomach, at least one hour before eating, to ensure it works correctly. Regulatory documents suggest that alcohol consumption be discussed with a healthcare provider, as consuming alcohol can increase stomach acid production and may reduce the medicine's effectiveness.

Q: Is Zugeryl generally considered safe for older adults?

A: Official information does not specify problems that would limit its use solely based on age. However, older patients may experience increased sensitivity to the medicine’s effects. Regulatory documents indicate that long-term use is associated with a higher potential risk of bone fractures in the hip, wrist, or spine in this population.

Q: Can someone with kidney problems take Zugeryl?

A: Official prescribing information indicates that the medicine should be used with caution in individuals with renal impairment (kidney problems). This is because the sodium bicarbonate component can affect the body's balance of electrolytes. Monitoring of kidney function may be considered necessary when using this medicine.

Q: Is Zugeryl safe to use during pregnancy or while breastfeeding?

A: Official regulatory documents indicate that there are no adequate studies in pregnant women, and use should only occur if the potential benefit outweighs the potential risk. For nursing mothers, the active ingredient Omeprazole is known to pass into breast milk. Regulatory guidance advises a decision to either discontinue the drug or discontinue breastfeeding.

Q: How is Zugeryl different from Brand X, which treats the same condition?

A: Regulatory information focuses on the medicine’s unique composition as a fixed-dose combination product. Unlike many PPIs that are delayed-release, this is an immediate-release formulation that pairs the PPI (Omeprazole) with an antacid (Sodium Bicarbonate). This dual action is designed to allow for faster onset of acid suppression.

Q: What is the maximum duration someone can safely take Zugeryl?

A: Therapy is typically structured as short-term courses, such as 4 to 8 weeks, for many conditions. Regulatory documents indicate that long-term use (over a year) is associated with increased risks for issues like bone fracture and Vitamin B12 deficiency. The official guidance recommends using the lowest effective dose for the shortest duration necessary for the condition.

Q: What are the symptoms of an allergic reaction to Zugeryl?

A: Official safety information lists signs of severe allergic reactions (hypersensitivity) that require immediate medical attention. These symptoms can include rash, itching, swelling (especially of the face, tongue, or throat), or difficulty breathing. Rare, severe skin reactions have also been documented in the official labeling.

Q: Are there any required monitoring tests while taking Zugeryl?

A: The regulatory label does not mandate specific routine monitoring tests for all patients. However, because long-term use is associated with a potential risk for low magnesium (Hypomagnesemia) and Vitamin B12 deficiency, a doctor may determine that blood or other laboratory tests are needed to monitor these effects.

Q: What happens if I miss a dose of Zugeryl?

A: If a dose is missed, official instructions advise taking it as soon as you recall. If it is almost time for your next scheduled dose, the regulatory guidance states to skip the missed dose and continue with the regular schedule. You should never take two doses at the same time to compensate for a missed dose.

Q: Can taking Zugeryl make you feel tired?

A: Official post-marketing experience reports for omeprazole-containing products have included instances of fatigue and a general feeling of weakness. However, the regulatory documentation does not classify these as common side effects.

Q: Can I take simple pain relievers (like ibuprofen) while using Zugeryl?

A: The official interaction profile does not specifically list common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as forbidden. However, regulatory documents caution that acid-reducing medicines may affect how certain other medicines are absorbed. Regulatory documents describe the importance of disclosing the use of all over-the-counter medicines to a healthcare professional.

Q: Do you need a prescription for Zugeryl?

A: The combination of Omeprazole and Sodium Bicarbonate is available in different strengths, which are sometimes sold as both prescription (Rx) and specific over-the-counter (OTC) formulations. The availability depends on the specific strength and its approved use for conditions like frequent heartburn.

Q: Is Zugeryl a controlled substance?

A: According to the regulatory labeling for this medicine, it is not classified as a controlled substance by the government. The official prescribing information also indicates that there is no known risk for abuse or addiction associated with this medicine.

Q: Why is Zugeryl sometimes given for conditions other than its main use? (Clarification on indications)

A: Official documents list the medicine's formal indications, which include more than just the primary use. It is approved to manage a variety of conditions related to excessive stomach acid, such as duodenal ulcers, erosive esophagitis, and Gastroesophageal Reflux Disease (GERD). The medicine is not approved for conditions that are not listed on the regulatory label.

Q: What should I do if a side effect of Zugeryl is worrying me?

A: The regulatory Medication Guide describes the process of immediately contacting a doctor or healthcare provider if you experience any serious adverse effects. The same guidance applies if a less severe side effect is persistent or causes significant concern.

Q: Does Zugeryl interact with alcohol?

A: While the regulatory documents do not list a specific drug interaction with alcohol, they advise patients to discuss alcohol consumption with a healthcare professional. Alcohol is known to increase stomach acid production, which may undermine the therapeutic goal of the medicine.

Q: Can Zugeryl cause changes in weight?

A: While not considered a common side effect, post-marketing surveillance reports for omeprazole-containing products have included cases of both sudden weight gain and unexplained weight loss. Official reports advise that significant or sudden weight changes be reported to a healthcare provider.

Q: Is Zugeryl likely to affect my mood or sleep?

A: The regulatory documents list nervous system effects reported in post-marketing surveillance for omeprazole. These include effects on sleep, such as insomnia and abnormal dreams, as well as changes in mood or thinking like agitation or depression.

Q: Can Zugeryl be stopped suddenly, or does it need to be done gradually?

A: The official guidance is clear that patients should not stop taking this medicine unless specifically directed to do so by a healthcare professional. Changing or discontinuing therapy, especially after prolonged use, is described in regulatory documents as requiring management by a healthcare professional.

Q: What is the half-life of Zugeryl?

A: According to the clinical pharmacology section, the plasma half-life of the active Omeprazole component is quite short, approximately 0.5 to 1 hour. However, the overall therapeutic effect is sustained because the Omeprazole works by irreversibly blocking the acid pumps. The sodium bicarbonate component provides an immediate neutralizing effect.

Q: Are there any official warnings about driving or operating machinery while taking Zugeryl?

A: While no absolute 'Do not drive' warning is present in the official label, patients are advised to use caution. This is because adverse reactions such as dizziness, drowsiness (somnolence), and blurred vision have been reported. Official reports advise caution, noting that if these side effects occur, operating machinery or driving may need to be avoided.

Q: Does Zugeryl have a 'Black Box' warning from the FDA?

A: A review of the regulatory labeling indicates that the Omeprazole/Sodium Bicarbonate combination does not currently carry a 'Black Box' Warning from the U.S. Food and Drug Administration (FDA).

Q: Is there a generic version of Zugeryl available?

A: Yes, the drug combination containing Omeprazole and Sodium Bicarbonate is available in both brand-name products and authorized generic versions.

Q: Is there a risk of dependency or addiction with Zugeryl?

A: The regulatory label for this medicine confirms that it is not associated with a risk of dependency or addiction. It is not classified as a controlled substance.

Q: Can taking Zugeryl affect lab test results?

A: Yes, regulatory documents note that this medicine can potentially interfere with certain blood tests, specifically tests for Chromogranin A (CgA). This interference may lead to inaccurate results for diagnosing certain conditions. It is important to inform your doctor or lab personnel if you are taking this medicine before having blood work done.

Q: Does Zugeryl affect blood pressure?

A: Blood pressure changes are not listed as a common side effect in the official documentation. However, post-marketing reports for the medicine have included adverse events such as elevated blood pressure and tachycardia (fast heart rate).

Q: How do I know if Zugeryl is still working?

A: The official patient information suggests that the medicine is effective when the symptoms it is intended to treat—such as ulcer pain or heartburn—are relieved. If symptoms continue to occur or worsen despite taking the medicine as prescribed, patients are guided to consult their healthcare professional.

Q: Is Zugeryl used to prevent or treat a condition?

A: Official regulatory documents indicate that the medicine is approved for both the treatment of specific acid-related conditions like GERD and erosive esophagitis. It is also approved for the prevention of upper gastrointestinal tract bleeding in certain critically ill patients.

Q: What happens if I accidentally take two doses of Zugeryl?

A: The regulatory Medication Guide describes the process of immediately contacting a doctor or a Poison Control Center if too much medicine has been taken.

Q: How soon after starting Zugeryl should I schedule a follow-up appointment?

A: Official documents emphasize that the doctor should check your progress during regular visits to ensure the medicine is working effectively and to monitor for potential unwanted effects. The specific timing of follow-up appointments is determined by the healthcare provider based on the individual condition.

Q: What are the ingredients in Zugeryl besides the active drug?

A: The complete list of inactive ingredients is found on the official product label, as they can vary depending on whether it is a capsule or suspension form. These inactive components often include ingredients like gelatin, coloring agents (e.g., titanium dioxide), and various stabilizers.

Q: Does the time of day matter when taking Zugeryl?

A: The official labeling specifies that the medicine should be taken once daily and must be taken on an empty stomach, one hour before a meal. While no specific morning or evening preference is mentioned, taking the dose at a consistent time each day is described as generally recommended for maintaining effectiveness.

Q: Why do official documents list so many potential side effects for Zugeryl?

A: Regulatory agencies require official documents to list virtually all adverse events observed in patients during clinical trials and through post-marketing reports. This requirement ensures that healthcare providers and patients are fully informed about all reported risks, even if a direct causal link has not been scientifically proven.

Q: Are there any documented cases of overdose with Zugeryl?

A: Yes, the official labeling includes documented cases of overdose with omeprazole-containing products. Reported symptoms have included confusion, unusual sweating, and a fast heartbeat. In any instance of suspected overdose, contacting a doctor or emergency services immediately is the action described in official labeling.

Q: Does Zugeryl cause sun sensitivity?

A: Sun sensitivity, or photosensitivity, is not listed as a common adverse reaction in the regulatory documents. However, post-marketing reports have included instances of increased sensitivity of the skin to sunlight and severe sunburn in individuals taking omeprazole.

Q: What if I vomit shortly after taking Zugeryl?

A: Official instructions do not provide specific directions for vomiting. Since the medicine needs to be absorbed to work, if the capsule is expelled shortly after consumption, consultation with a healthcare professional is described as necessary to determine if an additional dose should be taken.

Q: Can Zugeryl affect fertility?

A: The official prescribing information does not provide direct human data on fertility. However, animal studies conducted on the Omeprazole component showed no evidence of impaired fertility.

How should Zugeryl be stored and disposed of?

Zugeryl capsules must be stored and handled according to the following official requirements to ensure product stability and safety.

Storage & Disposal Scope

Item Requirement/Classification
Labeled storage temperature requirements Store at Controlled Room Temperature, between 20 C and 25 C (68 F to 77 F). Brief excursions up to 30 C are permitted.
Light/moisture protection requirements Protect from light and excessive moisture or humidity.
Handling requirements Avoid excessive heat. Do not keep outdated medicine.
Packaging-related storage rules Keep the container tightly closed and store in a closed container.
Disposal instructions (as documented) Ask a healthcare professional how to dispose of unused or expired medicine.
Child-protection storage requirements Must be stored out of the sight and reach of children.

Official Storage and Disposal Statements

  • The capsules must be maintained at Controlled Room Temperature, with protection from light and moisture.
  • The medicine must be kept in its closed, tightly sealed container at all times.
  • Unused or expired medication requires disposal consultation with a healthcare professional.

Regulatory documents strictly define the environmental constraints for this product, requiring storage within the specified temperature range and mandating protection from environmental elements to maintain stability. The labeling dictates the container integrity rules and includes explicit instructions that the product must be stored inaccessible to children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zugeryl found in:

A-Z Index: